Orphan drug designation offers development incentives and potential market exclusivity
News
Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol
Phase 3 trial shows promising pain relief for acute pain patients
Innovative Health Initiative launches a trial aimed at ending Crohn’s Disease
Europe’s first biomarker trial seeks to prevent Crohn’s Disease onset
AstraZeneca receives positive recommendations for lung cancer treatments
NICE endorses Imfinzi and Tagrisso for enhanced lung cancer care
AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025
Preclinical data highlights potential in treating Alzheimer’s disease
EC approves lazertinib in combination with amivantamab for NSCLC patients
Combination therapy shows superior survival benefit over standard treatment
UK sees 70% increase in phase I advanced therapy clinical trials in 2024
Cell and Gene Therapy Catapult reveals significant growth in UK trials
Datapharm expands into US market through partnership with phactMI
Collaboration aims to enhance accessibility of medicines information
Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials
New partnership to advance precision medicine in lung cancer diagnosis
Actinogen boosts trial with Cambridge Cognition’s digital suite
Partnership aims to advance Alzheimer’s research with innovative tools
Owlstone Medical announces $27 million USD first close in Series E financing round
Funds to accelerate commercialisation and clinical trials of diagnostic tests
Oxford Drug Design achieves in vivo validation for novel cancer treatment
Promising results from mouse study lead to expanded trials
Pheno Therapeutics granted trial authorisation for MS candidate
First-in-human trial of PTD802 to commence following UK MHRA approval
Grifols pioneers high-tech analysis of plasma bank to detect Parkinson’s disease
Initiative aims to identify plasma-based biomarkers for early detection
AI set to revolutionise pharmaceutical R&D says GlobalData
Survey finds AI to enhance productivity and cut costs in the next 12 months
